Madagascar
Tuberculosis profile
| High HIV burden |
Population  2013 23 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 12 (7.7–16) 52 (34–69)
Mortality (HIV+TB only) 0.43 (0.32–0.54) 1.9 (1.4–2.4)
Prevalence  (includes HIV+TB) 95 (50–150) 413 (216–671)
Incidence  (includes HIV+TB) 53 (47–60) 233 (207–262)
Incidence (HIV+TB only) 0.99 (0.88–1.1) 4.3 (3.8–4.9)
Case detection, all forms (%) 50 (44–56)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.5 (0.1–1.3) 3.9 (0.5–14)
MDR-TB cases among notified pulmonary
TB cases
99 (20–260) 94 (12–330)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 17 808   1 531
Pulmonary, clinically diagnosed 1 991    
Extrapulmonary 5 231    
       
Total new and relapse 26 561    
Previously treated, excluding relapses 884    
Total cases notified 27 445    
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 144 (<1%) 262 (11%) 421
Laboratory-confirmed RR-/MDR-TB cases     26
Patients started on MDR-TB treatment     12
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 412 (20)
HIV-positive TB patients 82 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 82 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 82
Previously treated cases, excluding relapse, registered in 2012 77
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 5
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 2.9
% Funded domestically 7%
% Funded internationally 93%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-05 Data: www.who.int/tb/data